



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12(b))

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On August 7, 2018, Titan Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote upon the following proposals: (1) to elect eight directors, each to serve until our next annual meeting and until their respective successors are elected and qualified, (2) to amend the Company’s 2015 Omnibus Equity Incentive Plan to increase the number of shares authorized for awards thereunder from 2,500,000 to 3,500,000 and (3) to ratify the appointment of OUM & Co. LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018.

1. Election of Directors

Stockholders elected all of the Company’s nominees for director for one-year terms expiring on the next annual meeting of stockholders. The voting results were as follows:

|                            | FOR       | WITHHELD  | BROKER NON-VOTE |
|----------------------------|-----------|-----------|-----------------|
| Marc Rubin, M.D.           | 3,369,323 | 1,644,718 | 13,703,179      |
| Sunil Bhonsle              | 3,388,684 | 1,625,357 | 13,703,179      |
| Joseph A. Akers            | 3,185,553 | 1,828,488 | 13,703,179      |
| Rajinder Kumar, Ph.D.      | 3,719,875 | 1,294,166 | 13,703,179      |
| M. David MacFarlane, Ph.D. | 3,172,341 | 1,841,700 | 13,703,179      |
| James R. McNab, Jr.        | 3,861,475 | 1,152,566 | 13,703,179      |
| Federico Seghi Recli       | 3,695,028 | 1,319,013 | 13,703,179      |
| Scott A. Smith             | 3,200,881 | 1,813,160 | 13,703,179      |

2. Stockholders approved the amendment to the 2015 Omnibus Equity Incentive Plan. The voting results were as follows:

| FOR       | AGAINST   | ABSTAIN | BROKER NON-VOTE |
|-----------|-----------|---------|-----------------|
| 3,317,885 | 1,629,326 | 66,830  | 13,703,179      |

3. Ratification of Auditors

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 8-K

Stockholders ratified the appointment of OUM & Co. LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2017. The voting results were as follows:

| FOR        | AGAINST | ABSTAIN   |
|------------|---------|-----------|
| 16,022,982 | 932,056 | 1,762,182 |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 8, 2018 TITAN PHARMACEUTICALS, INC.

By: /s/ Sunil Bhonsle

Name: Sunil Bhonsle

Title: Chief Executive Officer and President